Please try another search
Coeptis Therapeutics Holdings, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 3 million compared to USD 7.96 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.4 a year ago. Diluted loss per share from continuing operations was USD 0.08 compared to USD 0.4 a year ago.
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | ||||
Gross Profit | ||||
Operating Income | -2.92 | -3.63 | -7.81 | -3.6 |
Net Income | -3 | -4.02 | -6.26 | -3.11 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 9.39 | 8.07 | 7.17 | 7.16 |
Total Liabilities | 5.03 | 3.76 | 2.16 | 4.67 |
Total Equity | 4.36 | 4.31 | 5.01 | 2.49 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -1.9 | -1.69 | -1.96 | -1.9 |
Cash From Investing Activities | -0.1 | 0.35 | -0.35 | |
Cash From Financing Activities | 1.56 | 1.75 | -0.225 | 3.39 |
Net Change in Cash | -0.44 | 0.058 | -1.83 | 1.14 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review